BEAM BEAM THERAPEUTICS INC Product Launches 8-K Filing 2024 - Clinical Trial Updates Beam Therapeutics presented positive early data from its BEACON clinical trial for BEAM-101 in treating severe sickle cell disease, showing all patients achieved high levels of hemoglobin F and improved health outcomes. Additionally, new preclinical data for the ESCAPE conditioning platform was shared, demonstrating effective engraftment and safety in non-human primates.Get access to all SEC 8-K filings of the BEAM THERAPEUTICS INC